Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Alexion Pharmaceuticals is teaming up with Amsterdam-based Complement Pharma to test its antibody that inhibits an immune-system protein called C6, which forms pores in cells, causing them to lyse. C6 inhibition in animal models for nerve injury, traumatic brain injury, and Guillain-Barré syndrome suggests the therapy could be useful for many neurodegenerative conditions. Complement will receive up to $17 million in milestone payments as it tests the compound in a Phase I clinical trial. Alexion also has an option to acquire Complement.
This article has been sent to the following recipient: